TYDAL-TIMI 78

TYDAL-TIMI 78 is a Phase 2B dose-ranging study of MAR001 in adults with elevated triglycerides and remnant cholesterol.

Part A MAIN RESULTS:
ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels
N Engl J Med. 2026 Nov 9. doi: 10.1056/NEJMoa2612463. Online ahead of print.

PRIMARY RESULTS PRESENTATIONS

TYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations (O’Donoghue, AHA 2026)

TYDAL Principal Investigators Drs. Michelle O’Donoghue and Nicholas Marston discuss the trial.

TYDAL on ClinicalTrials.gov

CONTACT US about TYDAL